Methadone treatment and its dangers;Metadonas ir gydymo juo pavojai

Medicina

Volumn 45, Issue 5, 2009, Pages 419-425

  Reingardiene, Dagmara ^a   Jodžiuniene, Liucija ^b   Lažauskas, Robertas ^c  

^a Kauno medicinos universiteto Reabilitacijos klinika   (Lithuania)

^b Reanimacijos ir intensyviosios terapijos skyrius   (Lithuania)

^c Kardiologijos institutas   (Lithuania)

Author keywords

Methadone; Opiates; Overdose

Indexed keywords

EID: 68949189540     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina45050053     Document Type: Review

References (51)

1. Pirnay S, Borron SW, Giudicelli CP, Tourneau J, Baud FJ, Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine associated and 35 methadone-associated deaths. Addiction 2004;99:978-88.
2. Kintz P, Villain M, Dumestre-Toulet V, Capolaghi B, Cirimele V. Methadone as a chemical weapon. Two fatal cases involving babies. Ther Drug Monit 2005;27:741-3.
3. Nelson LS. Opioids. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland MA, Lewin NA, Nelson LS. Goldfrank's toxicologic emergencies. New York: McGraw - Hill. Medical Publishing Division; 2006. p. 590-613.
4. LoVecchio FDO, Pizon A, Riley B, Sami A, D'Incognito C. Onset of symptoms after methadone overdose. Amer J Emerg Med 2007;25:57-9.
5. Fingelkurts AA, Kahkonen S, Fingelkurts AA, Kivisaari R, Borisov S, Puuskari V, et al. Composition of EEG oscillations and their temporal characteristics: methadone treatment. Int J Psychophysiol 2007;64:130-40.
6. Axelrod DJ, Reville B. Using methadone to treat opioidinduced hyperalgesia and refractory pain. J Opioid Manag 2007;3:113-4.
7. Terpening CM, Johnson WM. Methadone as an analgesic: a review of the risks and benefits. W V Med J 2007;103:14-8.
8. Fredheim OMS, Borchgrevink PC, Klepstad P, Kaasa S, Dale O. Long-term methadone for chronic pain: a pilot study of pharmacokinetic aspects. Eur J Pain 2007;11:599-604.
9. Wolff K. Characterization of methadone overdose: clinical consideration and the scientific evidence. Ther Drug Monit 2002;24:457-70.
10. Bryant WK, Galea S, Tracy M, Markham Piper T, Tardiff KJ, Vlahov D. Overdose death attributed to methadone and heroin in New York City, 1990-1998. Addiction 2004;99:846-54.
11. Schwartz RP, Brooner RK, Montoya ID, Currens M, Hayes M. A 12-year follow-up of a methadone medical maintenance program. Amer J Addictions 1999;8:293-9.
12. Trafton JA, Ramani A. Methadone: a new old drug with promises and pitfalls. Curr Pain Headache Rep 2009;13:24-30.
13. Cohen MR, Smetzer JL. Keeping patients safe from iatrogenic methadone overdoses. Hospital Pharmacy 2008;43:353-8.
14. Mercadante S, Ferrera P, Villari P, Casuccio A, Intravaia G, Mangione S. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 2009;37:632-41.
15. Gallagher R. Methadone: an effective, safe drug of first choice for pain management in frail older adults. Pain Med 2009; 10:287-8.
16. Manchikanti L, Manchikanti KN, Pampati V, Cash KA. Prevalence of side effects of prolonged low or moderate dose opioid therapy with concomitant benzodiazepine and for antidepressant therapy in chronic non-cancer pain. Pain Physician 2009;12:259-67.
17. Kennedy EM, Rockefeller JD. Methadone-associated overdose deaths. Factors contributing to increased deaths and efforts to prevent them. United States Government Accountability Office (GAO). 2009 March, p. 1-51. Available from: URL: http://www.gao.gov/new.items/d09341.pdf
18. Michels II, Sander G, Stöver H. Practice, problems and perspectives of opioid substitution treatment (OST) in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheits-schutz 2009;52:111-21.
19. Bouchard NC, Nelson LS. Opioids. In: Fink MP, Abraham E, Vincent JL, Kochanek PM. Textbook of critical care. 5th ed. USA: Elsevier Saunders; 2005. p. 1703-10.
20. Hahn IH, Nelson LS. Opioids. In: Brent J, Wallace KL, Burkhart KK, Phillips SD, Donovan JW. Critical care toxicology. USA: Elsevier Mosby; 2005. p. 611-9.
21. Hussain T, Ewer AK. Maternal methadone may cause arrhythmias in neonates. Acta Pediatr 2007;96:768-9.
22. Vucinovic M, Roje D, Vucinovic Z, Capkun V, Bucat M, Banovic I. Maternal and neonatal effects of substance abuse during pregnancy: our ten-year experience. Yonsei Med J 2008;49:705-13.
23. Jansson LM, Dipietro JA, Velez M, Elko A, Knauer H, Kivlighan KT. Maternal methadone dosing schedule and fetal neurobehaviour. J Matern Fetal Neonatal Med 2009;22:29-35.
24. Jansson LM, Choo RE, Harrow C, Velez M, Schroeder JR, Lowe R, et al. Concentrations of methadone in breast milk and plasma in the immediate perinatal period. J Hum Lact 2007;23:184-90.
25. Liu AJW, Nahan R. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics 2008;121:869.
26. Glatstein MM, Garcia-Bournissen F, Finkelstein Y, Koren G. Methadone exposure during lactation. Can Fam Physician 2008;54:1689-90.
27. DeBattista Ch, Schatzberg AF. The black book of psychotropic dosing and monitoring 2005. USA: MBL Communications, Inc.; 2005. p. 16-20, 44-5.
28. Vlahov D, O'Driscoll P, Mehta SH, Ompad DS, Gern R, Galai N, et al. Risk factors for methadone outside treatment programs: implications for HIV treatment among injection drug users. Addiction 2007;102:771-7.
29. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Amer Heart J 2007;153:891-9.
30. Teplin D, Raz B, Daiter J, Varenbut, Plater-Zyberk C. Screening for alcohol use patterns among methadone maintenance patients. Amer J Drug Alcohol Abuse 2007;33:179-83.
31. Stenbacka M, Beck O, Leifman A, Romelsjo A, Helander A. Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment. Drug Alcohol Rev 2007;26:55-63.
32. Prosser JM, Mills A, Rhim ES, Perrone J. Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus. Int J Emerg Med 2008;1:217-20.
33. Armstrong SC, Wynn GH, Sandson NB. Pharmacokinetic drug interactions of synthetic opiate analgesics. Psychosomatics 2009;50:169-76.
34. Fugelstad A, Stenbacka M, Leifman A, Nylander M, Thiblin I. Methadone maintenance treatment: the balance between lifesaving treatment and fatal poisoning. Addiction 2007;102:406-12.
35. Atdjian S, Dhopesh V, Yu E, Fudala PJ. Methadone overdose in an opiate-naive patient. Amer J Addict 1999;8:170-1.
36. Kerr T, Fairbairn N, Tyndall M, Marsh D, Li K, Montaner J, et al. Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Dependence 2007;87:39-45.
37. Burns L, Mattick RP, Lim K, Wallace C. Methadone in pregnancy: treatment retention and neonatal outcomes. Addiction 2007;102:264-70.
38. Wang D, Teichtahl H, Goodman C, Drummer O, Grunstein RR, Kronborg I. Subjective daytime sleepiness and daytime function in patients on stable methadone maintenance treatment: possible mechanisms. J Clin Sleep Med 2008;4:557-62.
39. Ehret GB, Desmeules JA, Broers B. Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology. Expert Opin Drug Saf 2007;6:289-303.
40. Routhier DD, Katz KD, Brooks DE. QTc prolongation and torsades de pointes associated with methadone therapy. J Emerg Med 2007;32:275-8.
41. Stringer J, Welsh C, Tomasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. Am J Health Syst Pharm 2009;66:825-33.
42. C interval screening in methadone treatment. Ann Intern Med 2009;150:387-95.
43. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MCP. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007; 167:2469-75.
44. C interval: what are the practical implications? J Addict Dis 2008;27:1-4.
45. Athanasos P, Farquharson AL, Compton P, Psaltis P, Hay J. Electrocardiogram characteristics of methadone and buprenorphine maintained subjects. J Addict Dis 2008;27:31-5.
46. Orman JS, Keating GM. Buprenorphine/Naloxone: a review of its use in the treatment of opioid dependence. Drugs 2009; 69:577-607.
47. Gibson AE, Degenhardt LJ. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. Drug Alcohol Rev 2007;26:405-10.
48. Shah N, Lathrop SL, Landen MG. Unintentional methadonerelated overdose death in New Mexico (USA) and implications for surveillance, 1998-2002. Addiction 2004;100:176-88.
49. Webb L, Oyefeso A, Schifano F, Cheeta S, Pollard M, Ghodse AH. Cause and manner of death in drug-related fatality: an analysis of drug-related deaths recorded by coroners in England and Wales in 2000. Drug Alcohol Depend 2003;72: 67-74.
50. Hickman M, Madden P, Henry J, Baker A, Wallace C, Wakefield J, et al. Trends in drug overdose deaths in England and Wales 1993-98: methadone does not kill more people than heroin. Addiction 2003;98:419-25.
51. Oyefeso A, Ghodse H, Clancy C, Corkery J, Goldfinch R. Drug abuse-related mortality: a study of teenage addicts over a 20-year period. Soc Psychiatry Psychiatr Epidemiol 1999;34: 437-41.